Couto, Suzana

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology

Protein Degradation and InhibitorsPharmacological Effects and Toxicity Studies

Cited by 338

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 221

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Bjorklund, C. C., Kang, J., Amatangelo, M., Polonskaia, A., Katz, M., Chiu, H., Couto, S., Wang, M., Ren, Y., Ortiz, M., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 205

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 203

UBE2G1 governs the destruction of cereblon neomorphic substrates

Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 78

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 72

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

Franssen, L. E., Nijhof, I. S., Couto, S., Levin, M.-D., Bos, G. M. J., Broijl, A., Klein, S. K., Ren, Y., Wang, M., Koene, H. R., et al. (2018) · Haematologica

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 66

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

Zhang, M., Haughey, M., Wang, N.-Y., Blease, K., Kapoun, A. M., Couto, S., Belka, I., Hoey, T., Groza, M., Hartke, J., et al. (2020) · PLOS ONE

Wnt/β-catenin signaling in development and cancerLiver physiology and pathology

Cited by 48

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial

Ferreri, A. J. M., Sassone, M., Zaja, F., Re, A., Spina, M., Rocco, A. D., Fabbri, A., Stelitano, C., Frezzato, M., Rusconi, C., et al. (2017) · The Lancet Haematology

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 32

Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response

Reiss, D. J., Do, T., Kuo, D., Gray, V. E., Olson, N. E., Lee, C.-W., Young, M. H., Srinivasan, S., Gray, F. D., Fox, B., et al. (2019) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 30